Muscle Atrophy - Pipeline Review, H2 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 3, 2019--
The “Muscle Atrophy - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides an overview of the Muscle Atrophy (Musculoskeletal Disorders) pipeline landscape.
The review provides comprehensive information on the therapeutics under development for Muscle Atrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Muscle Atrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscle Atrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical, Discovery and Unknown stages are 7, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Muscle Atrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/wfrwzu
View source version on businesswire.com:https://www.businesswire.com/news/home/20191203006022/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 12/03/2019 04:10 PM/DISC: 12/03/2019 04:10 PM